Andrew Cortez, DO
Nephrology · Layton, UTNPI 1902882806
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 28.4% of the total.
Across 127 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$748
- Travere Therapeutics, Inc.$226
- Amgen$213
- Calliditas Therapeutics US Inc.$200
- Otsuka America Pharmaceutical, Inc.$175
- Vifor Pharma, Inc.$157
- plus $917 from 17 others
Across 25 payments — averaging $7054.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$176K
What the payments were for
- Food & beverage$2,62299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $748 |
| Travere Therapeutics, Inc. | 5 | $226 |
| Amgen(2 entities) | 12 | $213 |
| Calliditas Therapeutics US Inc. | 9 | $200 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Vifor Pharma, Inc. | 8 | $157 |
| ANI Pharmaceuticals, Inc. | 9 | $135 |
| Fresenius USA Marketing, Inc. | 6 | $113 |
| Akebia Therapeutics Inc | 6 | $113 |
| OPKO Pharmaceuticals, LLC | 6 | $103 |
| GSK | 5 | $73 |
| Nxstage Medical, Inc. | 3 | $49 |
| Novartis | 3 | $47 |
| Boehringer Ingelheim | 2 | $46 |
| Shire North American Group Inc | 2 | $41 |
| Ardelyx, Inc. | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Bayer | 2 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Cormedix Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,636 in reported general payments places this provider in the 70th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 72 | $90,652 |
| JardianceEmpagliflozin | 69 | $59,543 |
| VelphoroSucroferric Oxyhydroxide | 15 | $50,061 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $25,805 |
| Sevelamer Carbonate | 25 | $6,096 |
| Calcitriol | 108 | $2,742 |
| Losartan Potassium | 156 | $1,521 |
| Carvedilol | 131 | $1,408 |
| Tacrolimus | 14 | $1,348 |
| Torsemide | 60 | $1,335 |
| Furosemide | 130 | $1,013 |
| Hydralazine Hcl | 45 | $990 |
| Amlodipine Besylate | 88 | $932 |
| Chlorthalidone | 24 | $926 |
| Famotidine | 34 | $746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $748 | $116,45789 claims |
| Boehringer IngelheimJardiance | $46 | $59,54369 claims |
| Fresenius USA Marketing, Inc.Velphoro | $113 | $50,06115 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $135 | $33118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 74 nephrology providers in Utah.
Other nephrology in Layton
- Ryan McDonaldLayton$3K
- Shariq AhmadLayton$763
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Anitha VijayanMurray$118K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
- Srinivasa BeddhuSalt Lake City$8K
- George JaradSaint George$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.